Nuclea Energy, developer of small nuclear reactors, has applied for an IPO on the US stock market, aiming to raise $50 million.
Nuclea Energy (NCLA.US), dedicated to developing small nuclear reactors for off-grid markets and data centers, submitted an application to the Securities and Exchange Commission (SEC) on Monday, planning to raise up to $50 million through an initial public offering.
Nuclea Energy (NCLA.US), dedicated to developing small modular reactors for off-grid markets and data centers, submitted an application to the U.S. Securities and Exchange Commission (SEC) on Monday, April 13, to raise up to $50 million through an initial public offering (IPO).
The company plans to issue 5.6 million shares of stock at a price range of $8 to $10 per share. At the midpoint of this range, Nuclea Energy's market value would reach $354 million.
Nuclea Energy's core product is the "Morpheus small modular reactor," a transportable, factory-built, sealed-core nuclear reactor designed for use in remote Arctic regions and indigenous communities in Canada, mining and resource extraction industries, data centers, critical infrastructure, national defense, and security. The company is still in the development stage and has not generated any revenue.
Founded in 2023 and headquartered in Mississauga, Canada, the company plans to list on the NYSE American market under the ticker symbol "NCLA". The company had submitted a confidential filing for the IPO on December 19, 2025. Joseph Gunnar is the sole bookrunner for this transaction.
Related Articles

J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.

UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.

LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.






